Research Article
The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome
Table 1
Characteristics of the patients, severity of the ARDS, number of doranase alfa treatments, and outcome in the treatment group.
| | Characteristics | Number of patients (N = 39) | Outcome | Home | LTAC | Death/hospice |
| | Average age | 64 | | 33 | 2 | 4 | | Male | 25 | | 22 | 1 | 2 | | Female | 14 | | 11 | 1 | 2 |
| | Number of dornase alfa treatments | | | | | | | 1–4 | 8 | | 7 | 0 | 1 | | 5–10 | 23 | | 22 | 0 | 1 | | 11–15 | 3 | | 2 | 0 | 1 | | >15 | 5 | | 2 | 2 | 1 |
| | ARDS severity | | | | | | | Mild | 22 | | 22 | 0 | 0 | | Moderate | 7 | | 7 | 0 | 0 | | Severe | 10 | | 4 | 2 | 4 |
| | Comorbidities | | | | | | | HTN | 16 | | 15 | 0 | 1 | | HLD | 5 | | 4 | 0 | 1 | | DM | 6 | | 4 | 2 | 0 | | Malignancy | 2 | | 1 | 1 | 0 | | Transplant recipient | 1 | | 0 | 1 | 0 | | MI/CMO | 3 | | 3 | 0 | 0 | | PAF | 3 | | 2 | 1 | 0 | | Obstructive or restrictive lung disease | 5 | | 3 | 0 | 2 | | Pesticide exposure | 1 | | 0 | 0 | 1 | | CKD | 3 | | 2 | 1 | 0 |
| | Additional treatments | | | | | | | Dexamethasone | 20 | | 20 | 0 | 0 | | Dexamethasone + remdesivir | 15 | | 12 | 0 | 3 | | Dexamethasone + remdesivir + plasma | 1 | | 0 | 1 | 0 | | Dexamethasone + plasma + remdesivir + hemolung | 3 | | 1 | 1 | 1 |
|
|
